{"id":"https://openalex.org/W3116098017","doi":"https://doi.org/10.1016/j.msard.2020.102695","title":"Subgroup analysis of clinical and MRI outcomes in participants with a first clinical demyelinating event at risk of multiple sclerosis in the ORACLE-MS study","display_name":"Subgroup analysis of clinical and MRI outcomes in participants with a first clinical demyelinating event at risk of multiple sclerosis in the ORACLE-MS study","publication_year":2020,"publication_date":"2020-12-24","ids":{"openalex":"https://openalex.org/W3116098017","doi":"https://doi.org/10.1016/j.msard.2020.102695","mag":"3116098017","pmid":"https://pubmed.ncbi.nlm.nih.gov/33578191"},"language":"en","primary_location":{"id":"doi:10.1016/j.msard.2020.102695","doi":"https://doi.org/10.1016/j.msard.2020.102695","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.msard.2020.102695","pdf_url":"http://www.msard-journal.com/article/S2211034820307690/pdf","source":{"id":"https://openalex.org/S2764622253","display_name":"Multiple Sclerosis and Related Disorders","issn_l":"2211-0348","issn":["2211-0348","2211-0356"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Multiple Sclerosis and Related Disorders","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"http://www.msard-journal.com/article/S2211034820307690/pdf","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5020903163","display_name":"Bruce Cree","orcid":"https://orcid.org/0000-0001-7689-2533","observed_orcids":["https://orcid.org/0000-0001-7689-2533"]},"institutions":[{"id":"https://openalex.org/I180670191","display_name":"University of California, San Francisco","ror":"https://ror.org/043mz5j54","country_code":"US","type":"education","lineage":["https://openalex.org/I180670191"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Bruce A.C. Cree","raw_affiliation_strings":["UCSF Weill Institute for Neurosciences, San Francisco, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UCSF Weill Institute for Neurosciences, San Francisco, CA, USA","institution_ids":["https://openalex.org/I180670191"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5050509909","display_name":"James D. Bowen","orcid":"https://orcid.org/0000-0002-4258-250X","observed_orcids":["https://orcid.org/0000-0002-4258-250X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"James D. Bowen","raw_affiliation_strings":["Multiple Sclerosis Center, Swedish Neuroscience Institute, Seattle, WA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Multiple Sclerosis Center, Swedish Neuroscience Institute, Seattle, WA, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5063615479","display_name":"Hans\u2010Peter Hartung","orcid":"https://orcid.org/0000-0002-0614-6989","observed_orcids":["https://orcid.org/0000-0002-0614-6989"]},"institutions":[{"id":"https://openalex.org/I4210089242","display_name":"D\u00fcsseldorf University Hospital","ror":"https://ror.org/006k2kk72","country_code":"DE","type":"healthcare","lineage":["https://openalex.org/I4210089242"]},{"id":"https://openalex.org/I44260953","display_name":"Heinrich Heine University D\u00fcsseldorf","ror":"https://ror.org/024z2rq82","country_code":"DE","type":"education","lineage":["https://openalex.org/I44260953"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Hans-Peter Hartung","raw_affiliation_strings":["Department of Neurology, University Hospital of D\u00fcsseldorf, Medical Faculty, Heinrich-Heine-Universit\u00e4t, D\u00fcsseldorf, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Neurology, University Hospital of D\u00fcsseldorf, Medical Faculty, Heinrich-Heine-Universit\u00e4t, D\u00fcsseldorf, Germany","institution_ids":["https://openalex.org/I4210089242","https://openalex.org/I44260953"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025462803","display_name":"Patrick Vermersch","orcid":"https://orcid.org/0000-0003-0997-8817","observed_orcids":["https://orcid.org/0000-0003-0997-8817"]},"institutions":[{"id":"https://openalex.org/I154526488","display_name":"Inserm","ror":"https://ror.org/02vjkv261","country_code":"FR","type":"government","lineage":["https://openalex.org/I154526488"]},{"id":"https://openalex.org/I2279609970","display_name":"Universit\u00e9 de Lille","ror":"https://ror.org/02kzqn938","country_code":"FR","type":"education","lineage":["https://openalex.org/I2279609970"]},{"id":"https://openalex.org/I3018718406","display_name":"Centre Hospitalier Universitaire de Lille","ror":"https://ror.org/02ppyfa04","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I3018718406"]},{"id":"https://openalex.org/I4387155073","display_name":"Lille Neurosciences & Cognition","ror":"https://ror.org/04p94ax69","country_code":"FR","type":"facility","lineage":["https://openalex.org/I154526488","https://openalex.org/I2279609970","https://openalex.org/I3018718406","https://openalex.org/I4387155073"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Patrick Vermersch","raw_affiliation_strings":["University of Lille, INSERM U1172, Lille Neurosciences and Cognition, CHU Lille, FHU Imminent, F-59000 Lille, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Lille, INSERM U1172, Lille Neurosciences and Cognition, CHU Lille, FHU Imminent, F-59000 Lille, France","institution_ids":["https://openalex.org/I154526488","https://openalex.org/I2279609970","https://openalex.org/I3018718406","https://openalex.org/I4387155073"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5067769834","display_name":"Bruce Hughes","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Bruce Hughes","raw_affiliation_strings":["MercyOne Ruan Multiple Sclerosis Center, Des Moines, IA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"MercyOne Ruan Multiple Sclerosis Center, Des Moines, IA, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5104533563","display_name":"Doris Damian","orcid":"https://orcid.org/0000-0002-9562-9746","observed_orcids":["https://orcid.org/0000-0002-9562-9746"]},"institutions":[{"id":"https://openalex.org/I164928964","display_name":"Merck KGaA, Darmstadt (Germany)","ror":"https://ror.org/04b2dty93","country_code":"DE","type":"company","lineage":["https://openalex.org/I164928964"]},{"id":"https://openalex.org/I4405266695","display_name":"Merck Healthcare KGaA, Darmstadt (Germany)","ror":"https://ror.org/04vpzfb52","country_code":"DE","type":"company","lineage":["https://openalex.org/I164928964","https://openalex.org/I4405266695"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Doris Damian","raw_affiliation_strings":["EMD Serono Research & Development Institute, Inc., Billerica, MA, USA, an affiliate of Merck KGaA, Darmstadt, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"EMD Serono Research & Development Institute, Inc., Billerica, MA, USA, an affiliate of Merck KGaA, Darmstadt, Germany","institution_ids":["https://openalex.org/I164928964","https://openalex.org/I4405266695"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5037407336","display_name":"Yann Hyvert","orcid":"https://orcid.org/0009-0006-4700-0296","observed_orcids":["https://orcid.org/0009-0006-4700-0296"]},"institutions":[{"id":"https://openalex.org/I164928964","display_name":"Merck KGaA, Darmstadt (Germany)","ror":"https://ror.org/04b2dty93","country_code":"DE","type":"company","lineage":["https://openalex.org/I164928964"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Yann Hyvert","raw_affiliation_strings":["Merck KGaA, Darmstadt, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck KGaA, Darmstadt, Germany","institution_ids":["https://openalex.org/I164928964"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5010771032","display_name":"Fernando Dangond","orcid":"https://orcid.org/0000-0002-6723-4229","observed_orcids":["https://orcid.org/0000-0002-6723-4229"]},"institutions":[{"id":"https://openalex.org/I164928964","display_name":"Merck KGaA, Darmstadt (Germany)","ror":"https://ror.org/04b2dty93","country_code":"DE","type":"company","lineage":["https://openalex.org/I164928964"]},{"id":"https://openalex.org/I4405266695","display_name":"Merck Healthcare KGaA, Darmstadt (Germany)","ror":"https://ror.org/04vpzfb52","country_code":"DE","type":"company","lineage":["https://openalex.org/I164928964","https://openalex.org/I4405266695"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Fernando Dangond","raw_affiliation_strings":["EMD Serono Research & Development Institute, Inc., Billerica, MA, USA, an affiliate of Merck KGaA, Darmstadt, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"EMD Serono Research & Development Institute, Inc., Billerica, MA, USA, an affiliate of Merck KGaA, Darmstadt, Germany","institution_ids":["https://openalex.org/I164928964","https://openalex.org/I4405266695"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5048524048","display_name":"Andrew R. Galazka","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I164928964","display_name":"Merck KGaA, Darmstadt (Germany)","ror":"https://ror.org/04b2dty93","country_code":"DE","type":"company","lineage":["https://openalex.org/I164928964"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Andrew Galazka","raw_affiliation_strings":["Merck KGaA, Darmstadt, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck KGaA, Darmstadt, Germany","institution_ids":["https://openalex.org/I164928964"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5064084228","display_name":"Megan Grosso","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I164928964","display_name":"Merck KGaA, Darmstadt (Germany)","ror":"https://ror.org/04b2dty93","country_code":"DE","type":"company","lineage":["https://openalex.org/I164928964"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Megan Grosso","raw_affiliation_strings":["EMD Serono, Inc., Rockland, MA, USA, an affiliate of Merck KGaA, Darmstadt, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"EMD Serono, Inc., Rockland, MA, USA, an affiliate of Merck KGaA, Darmstadt, Germany","institution_ids":["https://openalex.org/I164928964"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103223044","display_name":"Daniel Lee Jones","orcid":"https://orcid.org/0000-0003-3749-2443","observed_orcids":["https://orcid.org/0000-0003-3749-2443"]},"institutions":[{"id":"https://openalex.org/I164928964","display_name":"Merck KGaA, Darmstadt (Germany)","ror":"https://ror.org/04b2dty93","country_code":"DE","type":"company","lineage":["https://openalex.org/I164928964"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Daniel L. Jones","raw_affiliation_strings":["EMD Serono, Inc., Rockland, MA, USA, an affiliate of Merck KGaA, Darmstadt, Germany"],"raw_orcid":"https://orcid.org/0000-0003-3749-2443","affiliations":[{"raw_affiliation_string":"EMD Serono, Inc., Rockland, MA, USA, an affiliate of Merck KGaA, Darmstadt, Germany","institution_ids":["https://openalex.org/I164928964"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5002866949","display_name":"Thomas P. Leist","orcid":"https://orcid.org/0000-0002-8924-8891","observed_orcids":["https://orcid.org/0000-0002-8924-8891"]},"institutions":[{"id":"https://openalex.org/I149251103","display_name":"Thomas Jefferson University","ror":"https://ror.org/00ysqcn41","country_code":"US","type":"education","lineage":["https://openalex.org/I149251103"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Thomas P. Leist","raw_affiliation_strings":["Comprehensive Multiple Sclerosis Center, Jefferson University, Philadelphia, PA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Comprehensive Multiple Sclerosis Center, Jefferson University, Philadelphia, PA, USA","institution_ids":["https://openalex.org/I149251103"]}]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":10,"corresponding_author_ids":["https://openalex.org/A5020903163"],"corresponding_institution_ids":["https://openalex.org/I180670191"],"apc_list":{"value":3050,"currency":"USD","value_usd":3050},"apc_paid":{"value":3050,"currency":"USD","value_usd":3050},"fwci":0.9847,"has_fulltext":true,"cited_by_count":12,"citation_normalized_percentile":{"value":0.7586784,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":94,"max":97},"biblio":{"volume":"49","issue":null,"first_page":"102695","last_page":"102695"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10137","display_name":"Multiple Sclerosis Research Studies","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10137","display_name":"Multiple Sclerosis Research Studies","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11827","display_name":"Polyomavirus and related diseases","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10469","display_name":"Psoriasis: Treatment and Pathogenesis","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/multiple-sclerosis","display_name":"multiple sclerosis","score":0.5659999847412109},{"id":"https://openalex.org/keywords/conversion-to-clinically-definite-multiple-sclerosis","display_name":"conversion to clinically definite multiple sclerosis","score":0.8519999980926514},{"id":"https://openalex.org/keywords/subgroup-analysis","display_name":"subgroup analysis","score":0.8939999938011169},{"id":"https://openalex.org/keywords/t2-lesions","display_name":"T2 lesions","score":0.8640000224113464},{"id":"https://openalex.org/keywords/mri-lesion-progression","display_name":"MRI lesion progression","score":0.48500001430511475},{"id":"https://openalex.org/keywords/predictors-of-disease-progression","display_name":"predictors of disease progression","score":0.5040000081062317},{"id":"https://openalex.org/keywords/relapsing-multiple-sclerosis","display_name":"relapsing multiple sclerosis","score":0.6840000152587891},{"id":"https://openalex.org/keywords/treatment-response-prediction","display_name":"treatment response prediction","score":0.33799999952316284},{"id":"https://openalex.org/keywords/poser-criteria","display_name":"Poser criteria","score":0.8050000071525574},{"id":"https://openalex.org/keywords/relapse-rate","display_name":"relapse rate","score":0.367000013589859},{"id":"https://openalex.org/keywords/relapse-severity","display_name":"relapse severity","score":0.3199999928474426}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9164441823959351},{"id":"https://openalex.org/C2780640218","wikidata":"https://www.wikidata.org/wiki/Q8277","display_name":"Multiple sclerosis","level":2,"score":0.9106689691543579},{"id":"https://openalex.org/C2779200787","wikidata":"https://www.wikidata.org/wiki/Q414030","display_name":"Cladribine","level":2,"score":0.8827192783355713},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5593100190162659},{"id":"https://openalex.org/C2780084366","wikidata":"https://www.wikidata.org/wiki/Q37732","display_name":"Demographics","level":2,"score":0.5288808345794678},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.46128979325294495},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.458008736371994},{"id":"https://openalex.org/C187960798","wikidata":"https://www.wikidata.org/wiki/Q7631152","display_name":"Subgroup analysis","level":3,"score":0.4152524173259735},{"id":"https://openalex.org/C2776036978","wikidata":"https://www.wikidata.org/wiki/Q425137","display_name":"Fingolimod","level":3,"score":0.4102102518081665},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.35480719804763794},{"id":"https://openalex.org/C44249647","wikidata":"https://www.wikidata.org/wiki/Q208498","display_name":"Confidence interval","level":2,"score":0.15340590476989746},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.11651352047920227},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.09443485736846924},{"id":"https://openalex.org/C149923435","wikidata":"https://www.wikidata.org/wiki/Q37732","display_name":"Demography","level":1,"score":0.06930273771286011},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0},{"id":"https://openalex.org/C144024400","wikidata":"https://www.wikidata.org/wiki/Q21201","display_name":"Sociology","level":0,"score":0.0}],"mesh":[{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008279","descriptor_name":"Magnetic Resonance Imaging","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009103","descriptor_name":"Multiple Sclerosis","qualifier_ui":"Q000000981","qualifier_name":"diagnostic imaging","is_major_topic":true},{"descriptor_ui":"D009103","descriptor_name":"Multiple Sclerosis","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D009103","descriptor_name":"Multiple Sclerosis","qualifier_ui":"Q000453","qualifier_name":"epidemiology","is_major_topic":true},{"descriptor_ui":"D012189","descriptor_name":"Retrospective Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017338","descriptor_name":"Cladribine","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D018450","descriptor_name":"Disease Progression","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1016/j.msard.2020.102695","doi":"https://doi.org/10.1016/j.msard.2020.102695","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.msard.2020.102695","pdf_url":"http://www.msard-journal.com/article/S2211034820307690/pdf","source":{"id":"https://openalex.org/S2764622253","display_name":"Multiple Sclerosis and Related Disorders","issn_l":"2211-0348","issn":["2211-0348","2211-0356"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Multiple Sclerosis and Related Disorders","raw_type":"journal-article"},{"id":"pmid:33578191","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/33578191","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Multiple sclerosis and related disorders","raw_type":"Journal Article"}],"best_oa_location":{"id":"doi:10.1016/j.msard.2020.102695","doi":"https://doi.org/10.1016/j.msard.2020.102695","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.msard.2020.102695","pdf_url":"http://www.msard-journal.com/article/S2211034820307690/pdf","source":{"id":"https://openalex.org/S2764622253","display_name":"Multiple Sclerosis and Related Disorders","issn_l":"2211-0348","issn":["2211-0348","2211-0356"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Multiple Sclerosis and Related Disorders","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[],"awards":[{"id":"https://openalex.org/G4650595887","display_name":null,"funder_award_id":"NCT00725985","funder_id":"https://openalex.org/F4320311647","funder_display_name":"Merck KGaA"}],"funders":[{"id":"https://openalex.org/F4320311647","display_name":"Merck KGaA","ror":"https://ror.org/04b2dty93"},{"id":"https://openalex.org/F4320332200","display_name":"EMD Serono","ror":"https://ror.org/027zrs220"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W3116098017.pdf","grobid_xml":"https://content.openalex.org/works/W3116098017.grobid-xml"},"referenced_works_count":36,"referenced_works":["https://openalex.org/W1828576284","https://openalex.org/W1983692527","https://openalex.org/W2001356567","https://openalex.org/W2010432945","https://openalex.org/W2016149155","https://openalex.org/W2022770486","https://openalex.org/W2058214824","https://openalex.org/W2061639126","https://openalex.org/W2096479500","https://openalex.org/W2104301864","https://openalex.org/W2106654138","https://openalex.org/W2107424415","https://openalex.org/W2128361812","https://openalex.org/W2130355701","https://openalex.org/W2139204856","https://openalex.org/W2141919552","https://openalex.org/W2146802292","https://openalex.org/W2152633256","https://openalex.org/W2167992220","https://openalex.org/W2170442728","https://openalex.org/W2213379694","https://openalex.org/W2313649737","https://openalex.org/W2538608950","https://openalex.org/W2584413859","https://openalex.org/W2751578374","https://openalex.org/W2761038804","https://openalex.org/W2777074421","https://openalex.org/W2790446387","https://openalex.org/W2801562584","https://openalex.org/W2833295077","https://openalex.org/W2885694220","https://openalex.org/W2887206114","https://openalex.org/W2898529060","https://openalex.org/W2914053307","https://openalex.org/W2916040650","https://openalex.org/W2935861115"],"related_works":["https://openalex.org/W4389464839","https://openalex.org/W2966873362","https://openalex.org/W3134392354","https://openalex.org/W2994717592","https://openalex.org/W2128361812","https://openalex.org/W2291024466","https://openalex.org/W2761038804","https://openalex.org/W2554246898","https://openalex.org/W2964886628","https://openalex.org/W4405557779"],"abstract_inverted_index":{"BACKGROUND:":[0],"In":[1,267,320,426],"the":[2,24,35,47,52,97,107,128,182,247,250,268,279,322,333,432,438,454],"Phase":[3],"3,":[4],"96-week":[5],"ORACLE-MS":[6,108,129,183,433],"study,":[7,434],"cladribine":[8,100,133,138,251,273,301,328,435],"10":[9],"mg":[10],"tablets":[11,101,134,139,252,274,302,329,436],"(3.5":[12],"mg/kg":[13,16,254,276,331],"or":[14,56,62,154,165,177,220,345],"5.25":[15,140],"cumulative":[17,215,336],"dose":[18],"over":[19],"2":[20],"years)":[21],"significantly":[22,277],"reduced":[23,278,332,437],"rate":[25,341,350,357],"of":[26,54,90,99,104,158,167,173,181,264,281,300,305,313,335,340,349,356,383,392,405,421,431,440],"conversion":[27,199,234,282,306,406,422,441],"to":[28,40,198,200,230,233,235,283,407,423,442],"clinically":[29],"definite":[30],"multiple":[31,43,443,459],"sclerosis":[32,44,444],"(CDMS)":[33],"per":[34,46],"Poser":[36],"criteria":[37],"(henceforth":[38],"referred":[39],"as":[41],"CDMS),":[42],"(MS)":[45],"2005":[48],"McDonald":[49,205,240,292,410],"criteria,":[50],"and":[51,65,84,113,160,171,192,202,218,237,289,325,353,390,445,458,465],"number":[53,172,391],"new":[55,61,219,344],"persisting":[57],"T1":[58,168,216,337,384],"gadolinium-enhancing":[59],"(Gd+),":[60],"enlarging":[63,221,346],"T2,":[64],"combined":[66],"unique":[67],"active":[68],"(CUA)":[69],"lesions":[70,170,175,360,386,394],"versus":[71,296,361],"placebo":[72,362],"in":[73,102,106,127,309,448,453],"participants":[74,105,125,449],"with":[75,403,419,450],"a":[76],"first":[77],"clinical":[78],"demyelinating":[79],"event":[80],"(FCDE).":[81],"Patient":[82],"demographic":[83],"disease":[85,91,114],"characteristics":[86],"may":[87],"be":[88],"predictors":[89],"progression.":[92],"The":[93,190],"current":[94],"study":[95,109,130,184],"analyzed":[96],"effect":[98],"subgroups":[103,144,314,460],"by":[110,147,316,462],"baseline":[111,148,318,399,414,463],"demographics":[112,464],"characteristics.":[115,319,467],"METHODS:":[116],"This":[117,242],"analysis":[118,243,430],"retrospectively":[119],"examined":[120,416],"data":[121],"collected":[122],"from":[123],"616":[124],"enrolled":[126],"(placebo,":[131],"n=206;":[132,137],"3.5":[135,253,275,330],"mg/kg,":[136,141],"n=204).":[142],"Five":[143],"were":[145,185,196,228,307,400,417],"predetermined":[146],"demographics,":[149],"including":[150,163],"sex,":[151],"age":[152,373],"(<30":[153],"\u226530":[155],"years),":[156],"classification":[157,378],"FCDE,":[159],"lesion":[161,446,466],"characteristics,":[162],"absence":[164],"presence":[166,382],"Gd+":[169,217,338,385],"T2":[174,222,347,393],"(<9":[176],"\u22659).":[178],"Selected":[179],"endpoints":[180,195,213],"re-analyzed":[186],"for":[187,249,261],"these":[188],"subgroups.":[189],"primary":[191],"main":[193],"secondary":[194],"time":[197,232],"CDMS":[201,236,284],"MS":[203,238,290,408],"(2005":[204,239,291,409],"criteria),":[206,411],"respectively.":[207],"Secondary":[208],"magnetic":[209],"resonance":[210],"imaging":[211],"(MRI)":[212],"included":[214],"lesions.":[223],"Cox":[224,367],"proportional":[225,368],"hazards":[226,369],"models":[227,370],"used":[229],"evaluate":[231],"criteria).":[241],"focused":[244],"primarily":[245],"on":[246,303],"results":[248],"group":[255],"because":[256],"this":[257,427],"dosage":[258],"is":[259],"approved":[260],"relapsing":[262],"forms":[263],"MS.":[265],"RESULTS:":[266],"overall":[269,455],"intent-to-treat":[270],"(ITT)":[271],"population,":[272],"risk":[280,304,404,420,439],"(hazard":[285],"ratio":[286],"[HR]=0.326;":[287],"P<0.0001)":[288,295,397],"criteria;":[293],"HR=0.485;":[294],"placebo.":[297],"Similar":[298],"effects":[299],"observed":[308],"post":[310,428],"hoc":[311,429],"analyses":[312],"defined":[315,461],"various":[317],"both":[321],"ITT":[323,456],"population":[324,457],"across":[326],"subgroups,":[327],"numbers":[334],"(range":[339,348,355],"ratios:":[342,351,358],"0.106-0.399),":[343],"0.178-0.485),":[352],"CUA":[354],"0.154-0.384)":[359],"(all":[363],"nominal":[364,375,380,388,396],"P<0.03).":[365],"Multivariate":[366],"revealed":[371],"that":[372],"(HR=0.577,":[374],"P<0.0001),":[376,389],"FCDE":[377,452],"(HR=0.738,":[379],"P=0.0043),":[381],"(HR=0.554,":[387],"(HR=0.417,":[395],"at":[398],"factors":[401,415],"associated":[402,418],"whereas":[412],"no":[413],"CDMS.":[424],"CONCLUSION:":[425],"burden":[447],"an":[451]},"counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":2},{"year":2022,"cited_by_count":3},{"year":2021,"cited_by_count":3}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2021-01-05T00:00:00"}